Schrödinger reports second quarter 2026 financial results
ACV grew 27% to $29.6 million and Bunsen early access launched.
See the latest news and media coverage for Schrödinger. We track all announcements, press releases, and industry mentions in real time, all in one place.
Physics-based software platform for molecular discovery and design
schrodinger.comLast updated
In short: Schrödinger launched Bunsen, an agentic AI co-scientist, and expanded its drug discovery partnership with Bristol Myers Squibb.
ACV grew 27% to $29.6 million and Bunsen early access launched.
The companies will deploy Schrödinger's Bunsen AI co-scientist and expand its functionality with computational tools and RetroSynth to accelerate drug discovery.
The early access version leverages NVIDIA and Google Cloud platforms to help researchers execute complex workflows.
The company will host a conference call at 4:30 p.m. ET after markets close.
AI co-scientist Bunsen drives productivity gains amid software model shift.
The new arrangement will extend the use of Schrödinger’s technologies, including Bunsen and RetroSyn...
On July 27, 2026, Schrödinger Inc (SDGR), a leader in molecular discovery platforms, announced the...
Relay is a reminder that computational-discovery platforms are increasingly judged by clinical...
Track Schrödinger and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Schrödinger and other trending companies.